Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2016 1
2017 1
2018 1
2020 3
2021 4
2022 6
2023 9
2024 12
2025 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

39 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial.
Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, Finan PH, Griffiths RR. Davis AK, et al. JAMA Psychiatry. 2021 May 1;78(5):481-489. doi: 10.1001/jamapsychiatry.2020.3285. JAMA Psychiatry. 2021. PMID: 33146667 Free PMC article. Clinical Trial.
OBJECTIVE: To investigate the effect of psilocybin therapy in patients with MDD. DESIGN, SETTING, AND PARTICIPANTS: This randomized, waiting list-controlled clinical trial was conducted at the Center for Psychedelic and Consciousness Research at Johns Hopkins …
OBJECTIVE: To investigate the effect of psilocybin therapy in patients with MDD. DESIGN, SETTING, AND PARTICIPANTS: This randomized, …
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.
Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, Cosimano MP, Klinedinst MA. Griffiths RR, et al. J Psychopharmacol. 2016 Dec;30(12):1181-1197. doi: 10.1177/0269881116675513. J Psychopharmacol. 2016. PMID: 27909165 Free PMC article. Clinical Trial.
Cancer patients often develop chronic, clinically significant symptoms of depression and anxiety. Previous studies suggest that psilocybin may decrease depression and anxiety in cancer patients. The effects of psilocybin were studied in 51 cancer patie …
Cancer patients often develop chronic, clinically significant symptoms of depression and anxiety. Previous studies suggest that ps …
Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial.
Raison CL, Sanacora G, Woolley J, Heinzerling K, Dunlop BW, Brown RT, Kakar R, Hassman M, Trivedi RP, Robison R, Gukasyan N, Nayak SM, Hu X, O'Donnell KC, Kelmendi B, Sloshower J, Penn AD, Bradley E, Kelly DF, Mletzko T, Nicholas CR, Hutson PR, Tarpley G, Utzinger M, Lenoch K, Warchol K, Gapasin T, Davis MC, Nelson-Douthit C, Wilson S, Brown C, Linton W, Ross S, Griffiths RR. Raison CL, et al. JAMA. 2023 Sep 5;330(9):843-853. doi: 10.1001/jama.2023.14530. JAMA. 2023. PMID: 37651119 Free PMC article.
IMPORTANCE: Psilocybin shows promise as a treatment for major depressive disorder (MDD). OBJECTIVE: To evaluate the magnitude, timing, and durability of antidepressant effects and safety of a single dose of psilocybin in patients with MDD. ...MAIN OUTCOMES AND MEASU …
IMPORTANCE: Psilocybin shows promise as a treatment for major depressive disorder (MDD). OBJECTIVE: To evaluate the magnitude, timing …
Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up.
Gukasyan N, Davis AK, Barrett FS, Cosimano MP, Sepeda ND, Johnson MW, Griffiths RR. Gukasyan N, et al. J Psychopharmacol. 2022 Feb;36(2):151-158. doi: 10.1177/02698811211073759. J Psychopharmacol. 2022. PMID: 35166158 Free PMC article. Clinical Trial.
AIMS: This study sought to examine the efficacy and safety of psilocybin through 12 months in participants with moderate to severe MDD who received psilocybin. METHODS: This randomized, waiting-list controlled study enrolled 27 patients aged 21-75 with …
AIMS: This study sought to examine the efficacy and safety of psilocybin through 12 months in participants with moderate to se …
Evidence-based consensus guidelines for the management of catatonia: Recommendations from the British Association for Psychopharmacology.
Rogers JP, Oldham MA, Fricchione G, Northoff G, Ellen Wilson J, Mann SC, Francis A, Wieck A, Elizabeth Wachtel L, Lewis G, Grover S, Hirjak D, Ahuja N, Zandi MS, Young AH, Fone K, Andrews S, Kessler D, Saifee T, Gee S, Baldwin DS, David AS. Rogers JP, et al. J Psychopharmacol. 2023 Apr;37(4):327-369. doi: 10.1177/02698811231158232. Epub 2023 Apr 11. J Psychopharmacol. 2023. PMID: 37039129 Free PMC article.
Long-term effects of psychedelic drugs: A systematic review.
Aday JS, Mitzkovitz CM, Bloesch EK, Davoli CC, Davis AK. Aday JS, et al. Neurosci Biobehav Rev. 2020 Jun;113:179-189. doi: 10.1016/j.neubiorev.2020.03.017. Epub 2020 Mar 16. Neurosci Biobehav Rev. 2020. PMID: 32194129
The bulk of this work was published in the last five years, with psilocybin being the most frequently administered drug. Enduring changes in personality/attitudes, depression, spirituality, anxiety, wellbeing, substance misuse, meditative practices, and mindfulness …
The bulk of this work was published in the last five years, with psilocybin being the most frequently administered drug. Enduring cha …
Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.
Lowe H, Toyang N, Steele B, Grant J, Ali A, Gordon L, Ngwa W. Lowe H, et al. Molecules. 2022 Apr 14;27(8):2520. doi: 10.3390/molecules27082520. Molecules. 2022. PMID: 35458717 Free PMC article. Review.
Psychedelic drugs such as N,N-DMT/DMT (N,N-dimethyltryptamine), 5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine), LSD (lysergic acid diethylamide), MDMA (3,4-methylenedioxymethamphetamine) and psilocybin have had significant value as an entheogen in spiritual, religious (shama …
Psychedelic drugs such as N,N-DMT/DMT (N,N-dimethyltryptamine), 5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine), LSD (lysergic acid diethylamid …
Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis.
Hinkle JT, Graziosi M, Nayak SM, Yaden DB. Hinkle JT, et al. JAMA Psychiatry. 2024 Dec 1;81(12):1225-1235. doi: 10.1001/jamapsychiatry.2024.2546. JAMA Psychiatry. 2024. PMID: 39230883 Free PMC article.
DATA SOURCES: The search for potentially eligible studies was conducted in the Scopus, MEDLINE, PsycINFO, and Web of Science databases from inception through February 8, 2024. STUDY SELECTION: Two independent reviewers screened articles of classic psychedelics (lysergic ac …
DATA SOURCES: The search for potentially eligible studies was conducted in the Scopus, MEDLINE, PsycINFO, and Web of Science databases from …
Psychedelic research at a crossroads.
Armstrong SB, Davis AK. Armstrong SB, et al. Science. 2024 Sep 20;385(6715):1255. doi: 10.1126/science.adt1024. Epub 2024 Sep 19. Science. 2024. PMID: 39298596
Although results of trials using MDMA for trauma or psilocybin for depression are promising, PAT is controversial because many questions about its safety and effectiveness are unanswered. This is evident in the recent ruling by the US Food and Drug Administration ag …
Although results of trials using MDMA for trauma or psilocybin for depression are promising, PAT is controversial because many …
Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial.
von Rotz R, Schindowski EM, Jungwirth J, Schuldt A, Rieser NM, Zahoranszky K, Seifritz E, Nowak A, Nowak P, Jäncke L, Preller KH, Vollenweider FX. von Rotz R, et al. EClinicalMedicine. 2022 Dec 28;56:101809. doi: 10.1016/j.eclinm.2022.101809. eCollection 2023 Feb. EClinicalMedicine. 2022. PMID: 36636296 Free PMC article.
BACKGROUND: Psilocybin has been suggested as a novel, rapid-acting treatment for depression. Two consecutive doses have been shown to markedly decrease symptom severity in an open-label setting or when compared to a waiting list group. ...MADRS and BDI scores were a …
BACKGROUND: Psilocybin has been suggested as a novel, rapid-acting treatment for depression. Two consecutive doses have been s …
39 results